🇺🇸 FDA
Patent

US 11911446

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

granted A61KA61K38/1709A61K38/2242

Quick answer

US patent 11911446 (Use of C-type natriuretic peptide variants to treat skeletal dysplasia) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K38/1709, A61K38/2242, A61K47/10, A61K47/12